These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19657721)

  • 41. A multicentre analysis of Clostridium difficile in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level.
    Deane J; Fouhy F; Ronan NJ; Daly M; Fleming C; Eustace JA; Shanahan F; Flanagan ET; Dupont L; Harrison MJ; Haworth CS; Floto A; Rea MC; Ross RP; Stanton C; Plant BJ
    J Infect; 2021 Mar; 82(3):363-370. PubMed ID: 33444699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
    Gómez S; Chaves F; Orellana MA
    Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of Clostridioides difficile associated diarrhea in hospitalized patients in five Brazilian centers: A multicenter, prospective study.
    Girão ES; de Melo Tavares B; Alves Dos Santos S; Gamarra GL; Rizek C; Martins RC; Perdigão Neto LV; Diogo C; Annibale Orsi T; Sanchez Espinoza EP; Paz Morales HM; da Silva Nogueira K; Maestri AC; Boszczowski I; Piastrelli F; Costa CL; Costa DV; Maciel G; Romão J; Guimarães T; Anne de Castro Brito G; Costa SF
    Anaerobe; 2020 Dec; 66():102267. PubMed ID: 33080372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
    Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
    J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI).
    Manthey CF; Dranova D; Christner M; Drolz A; Kluge S; Lohse AW; Fuhrmann V
    Crit Care; 2019 Dec; 23(1):399. PubMed ID: 31815650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections.
    Jamot S; Raghunathan V; Patel K; Kelly CR; Lim SH
    Infect Control Hosp Epidemiol; 2018 Mar; 39(3):302-306. PubMed ID: 29363436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiologic Trends in Clostridioides difficile Infections in a Regional Community Hospital Network.
    Turner NA; Grambow SC; Woods CW; Fowler VG; Moehring RW; Anderson DJ; Lewis SS
    JAMA Netw Open; 2019 Oct; 2(10):e1914149. PubMed ID: 31664443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
    Peretz A; Tkhawkho L; Pastukh N; Brodsky D; Halevi CN; Nitzan O
    BMC Infect Dis; 2016 Jun; 16():309. PubMed ID: 27334992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pilot study in Serbia by European Clostridium difficile Infection Surveillance Network.
    Jovanović M; van Dorp SM; Drakulović M; Papić D; Pavić S; Jovanović S; Lešić A; Korać M; Milošević I; Kuijper EJ
    Acta Microbiol Immunol Hung; 2019 Dec; 67(1):42-48. PubMed ID: 31813261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening of
    Baron SW; Ostrowsky BE; Nori P; Drory DY; Levi MH; Szymczak WA; Rinke ML; Southern WN
    Infect Control Hosp Epidemiol; 2020 Feb; 41(2):149-153. PubMed ID: 31822302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.
    Wang B; Lv Z; Zhang P; Su J
    Medicine (Baltimore); 2018 Jun; 97(25):e11219. PubMed ID: 29924052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease.
    Gholam-Mostafaei FS; Yadegar A; Aghdaei HA; Azimirad M; Daryani NE; Zali MR
    Curr Res Transl Med; 2020 Aug; 68(3):125-130. PubMed ID: 32414632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR
    J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection.
    Misawa K; Iketani O; Enoki Y; Taguchi K; Uno S; Uwamino Y; Hasegawa N; Matsumoto K
    J Infect Chemother; 2021 Oct; 27(10):1407-1412. PubMed ID: 34023223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011: A nationwide study.
    Ziakas PD; Joyce N; Zacharioudakis IM; Zervou FN; Besdine RW; Mor V; Mylonakis E
    Medicine (Baltimore); 2016 Aug; 95(31):e4187. PubMed ID: 27495022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of molecular testing on reported
    Ilieş I; Benneyan JC; Jabur TBC; Baker AW; Anderson DJ
    Infect Control Hosp Epidemiol; 2020 Mar; 41(3):306-312. PubMed ID: 31852562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan.
    Tokimatsu I; Shigemura K; Osawa K; Kinugawa S; Kitagawa K; Nakanishi N; Yoshida H; Arakawa S; Fujisawa M;
    J Infect Chemother; 2018 Aug; 24(8):641-647. PubMed ID: 29685855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China.
    Cui Y; Dong D; Zhang L; Wang D; Jiang C; Ni Q; Wang C; Mao E; Peng Y
    BMC Infect Dis; 2019 Nov; 19(1):961. PubMed ID: 31711425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.